Home > Publications database > Subjective and Objective Cancer-Related Cognitive Impairments Among Systemic and Radiation Therapy-Naïve Female Cancer Patients. > print

001     300631
005     20250427020248.0
024 7 _ |a 10.1002/cam4.70908
|2 doi
024 7 _ |a pmid:40259875
|2 pmid
024 7 _ |a altmetric:176359291
|2 altmetric
037 _ _ |a DKFZ-2025-00845
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Onyedibe, Maria Chidi Christiana
|0 P:(DE-He78)80f716879524b90b0ca1050b30f8279e
|b 0
|e First author
245 _ _ |a Subjective and Objective Cancer-Related Cognitive Impairments Among Systemic and Radiation Therapy-Naïve Female Cancer Patients.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745414903_30949
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C110#LA:C110#
520 _ _ |a Cancer-related cognitive impairment (CRCI) is a frequent and burdensome problem that is still insufficiently understood and managed. We investigated subjective and objective measures of CRCI, as recommended by the International Cancer and Cognition Task Force (ICCTF) in cancer patients prior to systemic or radiation therapy with respect to potential influencing or associated psychosocial, demographic, or lifestyle factors.Female patients with breast or gynecological tumors (n = 239, mean age = 55.5, SD = 11.6) prior to any systemic or radiation therapy completed validated subjective (FACT-Cog: perceived cognitive impairment [PCI], perceived cognitive ability [PCA], impact on quality of life [IQoL]) and objective measures of CRCI (Trail Making Test [TMT-A and -B], Controlled Oral Word Association Test [COWA], and Hopkins Verbal Learning Test-Revised [HVLT-R]). Association with cross-sectionally assessed age, body mass index, education, smoking, alcohol intake, sleep problems, social support, anxiety, and pain was investigated using multiple linear regression models.A quarter (25.1%) of patients showed indication for CRCI based on the PCI score. Subjective and objective CRCI measures showed no or only weak correlations, also when adjusting for age and education (partial Spearman correlations with each other, all |r| ≤ 0.21). Anxiety, sleep problems, and pain were significantly associated with low subjective cognitive function (PCI, PCA, and IQoL). Poor objective cognitive values (TMT, COWA, and HVLT-R) were mainly determined by higher age and lower education.Cancer-related cognitive impairment is not solely (chemo-)therapy-induced but may be triggered or influenced by anxiety, sleep problems, and pain. Addressing these issues early in the treatment phase could potentially alleviate perceived CRCI. The ICCTF-recommended neuropsychological tests do not adequately capture this CRCI prior to systemic or radiation therapy, but could serve as complementary tools to monitor cognitive changes over time, independent of psychosocial influences.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a anxiety
|2 Other
650 _ 7 |a breast cancer
|2 Other
650 _ 7 |a cancer‐related cognitive impairment
|2 Other
650 _ 7 |a neuropsychological tests
|2 Other
650 _ 7 |a sleep problem
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: epidemiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Breast Neoplasms: complications
|2 MeSH
650 _ 2 |a Breast Neoplasms: psychology
|2 MeSH
650 _ 2 |a Breast Neoplasms: therapy
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Genital Neoplasms, Female: complications
|2 MeSH
650 _ 2 |a Genital Neoplasms, Female: psychology
|2 MeSH
650 _ 2 |a Genital Neoplasms, Female: therapy
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
700 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 1
|e First author
|u dkfz
700 1 _ |a Bizer, Pauline
|0 P:(DE-He78)99e08c106da1c0aae8cb9f2dff77165f
|b 2
700 1 _ |a Zimmer, Philipp
|b 3
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1002/cam4.70908
|g Vol. 14, no. 8, p. e70908
|0 PERI:(DE-600)2659751-2
|n 8
|p e70908
|t Cancer medicine
|v 14
|y 2025
|x 2045-7634
909 C O |o oai:inrepo02.dkfz.de:300631
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)80f716879524b90b0ca1050b30f8279e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)99e08c106da1c0aae8cb9f2dff77165f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER MED-US : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:04:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:04:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:04:21Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-08T17:04:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 2 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 0 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21